Abstract Angiogenesis is crucial to the growth of malignant gliomas. Therefore, antiangiogenic therapy represents a new, promising therapeutic modality for malignant gliomas. This study was designed to define the malignant glioma cases most suitable for antiangiogenic therapy in humans and to demonstrate the efficacy of antiangiogenic therapy in animals. Protein expression of the most potent angiogenic factor, vascular endothelial growth factor (VEGF), and its specific natural inhibitor, soluble Flt-1, as well as vessel architecture, including vessel density, area, and diameter, was evaluated in human malignant glioma samples (24 glioblastomas, 13 anaplastic astrocytomas). Among these, VEGF >1000ng/ml, VEGF/soluble Fltl ratio >1, vessel density >30, and vessel area >7% were prognostic factors for malignant gliomas. Based on these results, we performed three different antiangiogenic experiments targeted to inhibit VEGF expression in a human malignant glioma (U87) mouse model: anti-VEGF neutralized antibody intraperitoneal injection; interferon-beta intramusclar injection; and transfection of an endogenous nonspecific angiogenesis inhibitor, thrombospondin-1, into glioma cells caused inhibition of VEGF secretion and/or mRNA expression and resulted in glioma growth inhibition of 70%, 84%, and 50%, respectively, compared with control. We conclude that malignant gliomas with high degrees of VEGF expression and vessel areas are good candidates for antiangiogenic therapy, especially that designed to inhibit VEGF expression.
Introduction
Angiogenesis is crucial to the growth of malignant gliomas. 13 Therefore, antiangiogenic therapy represents a promising therapeutic modality for malignant gliomas. 4 Currently defined endogenous angiogenic stimulators and inhibitors of neoplasms have been well described. 5 Especially, the balance between stimulators and inhibitors regulates angiogenesis of tumors, resulting in tumor growth. ~ Almost all of these factors have been investigated for gliomas, and these factors should be designed for glioma antiangiogenesis therapy. The evidence for glioma antiangiogenesis therapy, with and without chemotherapy, has been described in many animal experiments, which showed dramatic inhibition of glioma growth. 7' These include many anti-VEGF strategies, such as antisense, antibody, receptor antibody, etc. 9 Four angiogenesis inhibitors, interferon-beta, marimastat, suramin, and thalidomide, are now undergoing clinical trials. However, the results of these clinical trials have been limited. Further studies are needed to improve the efficacy of the therapy. This study was designed to define the malignant glioma cases most suitable for antiangiogenic therapy in humans and to demonstrate the efficacy of antiangiogenic therapy in animals.
Materials and methods

Angiogenic profiles of gliomas
Human malignant glioma samples (24 glioblastomas, 13 anaplastic astrocytomas) were stored at -80~ protein expression of the most potent angiogenic factor, VEGF, and its specific natural inhibitor; soluble Flt-1, was measured with ELISA (R&D Systems, Minneapolis, MN, USA). Vessel architecture, including vessel density, area, and diameter, were measured by CD31 stained sections using Windroof morphometry software (Sankou Shoji, Tokyo, Japan). By marking each vessel outline, vessel density per 0.13mm 2, vessel occupied area, vessel diameter, vessel perimeter, and vessel roundness were measured on three different areas. MIB-l(Immunotech, Maeseille Cedex, France) and p53 (DO7; DAKO, Glostrup, Denmark) positivities were measured. Based on these profiles, prognostic factors of malignant gliomas were investigated.
Antiangiogenic therapy for U87 mouse glioma model
We designed three different antiangiogenic experiments targeted to inhibit VEGF expression in the U87 mouse model of human malignant glioma? The first was an anti-VEGF neutralizing antibody experiment. In the second, an endogenous nonspecific angiogenesis inhibitor, thrombospondin-1, was transfected into glioma cells, U87. The third experiment involved intraperitoneal injection of interferon-beta. In each experiment, tumor growth, angiogenic profiles, and VEGF expression were evaluated.
Results
Angiogenic profiles and their relation to survival of gliomas
Our treatment strategy for malignant gliomas is total or subtotal removal, followed by 40Gy whole brain and 20Gy local boost irradiation combined with PAV (procarbazine ACNU, Vincristine) chemotherapy and interferon-[3. At recurrence, PE (cisplatin, etoposide) chemotherapy and/or immunotherapy, including locolesional natural killer or cytotoxic T lymphocyte injection, was carried out. The median survival rate of all malignant gliomas was 19.2 months (gliobtastoma 11.2 months, anaplastic astrocytoma 30.9 months).
VEGF concentration and sFlt-1 concentrations of more than 1000pg/mg were prognostic factors. A VEGF/sFlt-1 ratio more than 1 was the strongest prognostic factor. The median survival time was 11.3 months for ratios over 1 and 28.7 months for ratios under 1 (Table 1) . These results suggest that the balance of stimulators and inhibitors of angiogenesis is especially important for the angiogenic evaluation of malignant gliomas. Other angiogenic parameters, i.e., vessel density more than 30 and vessel area more than 7%, also predicted malignant glioma survival (Table 1) .
Anti-VEGF neutralizing antibody experiment
Intraperitoneal injection of 100 ~tg of VEGF antibody twice a week for 4 weeks inhibited glioma growth with the subcutaneous model (Fig. 1 ) and prolonged survival of intracranial glioma-bearing mice (data not shown). 
Days After Implantation
Thrombospondin-1 transfection
Thrombospondin-1 cDNA transfected into U87 using .fugene6. The thrombospondin-1 transefectant not only secreted a large amount of thrombospondin in the conditioned medium, but also secreted a decreased amount of VEGF in the conditioned medium compared with parent and control glioma cells. The growth of the transfectant in vivo in the mouse subcutaneous model was significantly slow compared with control ( Fig. 2) . Western blot analysis of transfectant glioma tissues showed decreased expression of VEGF as well as increased expression of thrombospondin-1 compared with control glioma tissues (data not shown).
Interferon-beta intraperitoneal injection
Low-dose (1 x 10 s units every day for 15 days) and highdose (5 • 10 s units) interferon-beta systemic treatment significantly inhibited subcutaneous growth of gliomas. After discontinuation of treatment, glioma growth restarted, suggesting that the growth-inhibitory effect of interferon-beta is cytostatic, not cytocidal (Fig. 3A) . In the glioma tissues, interferon-beta treatment remarkably upregulated the protein expression of IP-10, an endogenous inhibitor of angiogenesis, and down-regulated VEGF protein expression (Fig. 3B ).
VEGF-targeting antiangiogenesis experimental therapy for malignant gliomas.
Angiogenic profile of malignant gliomas
The importance of angiogenesis of malignant gliomas has been demonstrated by many investigations. However, the precise importance of the degree of angiogenesis varies according to the method used to measure it. Therefore, which malignant gliomas are most suitable for antiangiogenesis therapy is not clear. Among the parameters of angiogenesis, VEGF 1~ and its specific inhibitor, soluble Flt-1, are important. Soluble Fit-1 is a soluble form of VEGF receptor-1. Soluble Fltl is a part of the intracellular domain of Fltl and exists in the tissue with the soluble form. Because soluble Flt-1 has a VEGF-binding site, it inhibits binding of VEGF to the receptor." In our study, VEGF >1000pg/mg, VEGF/sFlt-1 ratio >1, vessel density >30/ 0.13mm a, and vessel area >7% were prognostic factors formalignant gliomas. The VEGF/sFLT-1 ratio was the strongest prognostic factor, which means that not only the amount of stimulators, but also the balance with a specific stimulator (e.g., VEGF) and its inhibitor (e.g., sFlt-1), is more reliable. Malignant gliomas that possess these angiogenic values should be suitable candidates for VEGFtargeting antiangiogenesis therapy.
Discussion
In this study, we demonstrated angiogenic profiles of malignant gliomas that are related to prognosis and three types of
VEGF-targeting antiangiogenesis therapy
Next, intraperitoneal injection of anti-VEGF antibody, transfection of thrombospondin-1 into glioma cells, and intraperitoneal injection of interferon-beta caused inhibition VEGF-neutralizing antibody is now clinically relevant for colon cancer and renal-cell carcinomaJ 2 These data, as well as our data prompt, us to use these compounds as antiangiogenesis molecules for malignant gliomas. The antiangiogenic function of thrombospondin-1 has been investigated for a long time. 1~ In vitro, TSP-1 transfectant inhibited the secretion of V E G F , and in vivo, TSP-1 transfectant glioma tissues had little V E G F expression compared with control. This molecular link between TSP1 and V E G F is a quite new finding and offers the possibility of antiangiogenic gene therapy 14 utilizing the TSPI molecule. Interferon-13 has been clinically used systemically and genetically] 5'~6 Our experimental result clearly shows its antiangiogenesis effect and its cytostatic, not cytocidal, effect. We emphasize that the target molecules of interferon-13, as an antiangiogenesis agent, are V E G F , as well as b F G F , 17 as stimulators of angiogenesis, and IP10 as an inhibitor of angiogenesis.
We conclude that malignant gliomas with a high degree of V E G F expression and vessel area are good candidates for antiangiogenic therapy. Targeting to inhibit V E G F expression is a promising therapy for malignant gliomas.
